Search results for "From ACP Journal Club"
GLP-1 RA plus SGLT-2 inhibitor vs. either drug alone reduces HbA1c and SBP
The finding that combining glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors improves glycemic control and systolic blood pressure (SBP) without increasing hypoglycemia is important, but additional cost-effectiveness research on the drugs is needed, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/12/11/9.htm
11 Dec 2020
SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes
Diabetic ketoacidosis (DKA) is rare with sodium-glucose co-transporter-2 (SGLT2) inhibitors but more common than with control medications, and clinicians should be vigilant in identifying euglycemic DKA in patients on these drugs, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/11/13/6.htm
13 Nov 2020
In obesity with T2DM, biliopancreatic diversion increased T2DM remission vs. medical and lifestyle therapy at 10 y
Previous research has shown short-term remission of type 2 diabetes after bariatric surgery, but a decade of data from this randomized trial should reassure patients of the favorable long-term benefits and safety of this intervention, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/06/11/9.htm
11 Jun 2021
In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs
A meta-analysis identified relative benefits of sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) based on individual cardiovascular and renal risks.
https://diabetes.acponline.org/archives/2021/06/11/8.htm
11 Jun 2021
In men who are overweight or obese, adding testosterone therapy reduced glucose intolerance/T2DM
A industry-funded trial found improved glucose control in men randomized to testosterone injections, but some of its claims were exaggerated, and routine use of testosterone therapy to prevent or reverse type 2 diabetes is not recommended, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/05/14/7.htm
14 May 2021
Studies show benefits of glucagon-like peptide-1 receptor agonists
A commentary reviewed the findings of REWIND, PIONEER 6, and PIONEER 4 trials, which studied the cardiovascular and glycemic control effects of dulaglutide, semaglutide, and liraglutide.
https://diabetes.acponline.org/archives/2019/10/11/7.htm
11 Oct 2019
In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding
Although an industry-funded trial found little net benefit overall from adding ticagrelor to aspirin, it's possible that some patients with higher ischemic risk and low bleeding risk could benefit, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/02/14/6.htm
14 Feb 2020
In screen-detected type 2 diabetes, intensive therapy did not differ from usual care for CV events at 10 years
Despite the lack of observed benefit in this analysis, primary care physicians should continue to operate under the reasonable assumption that addressing cardiovascular (CV) risk factors improves longevity, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/05/08/6.htm
8 May 2020
In acute ischemic stroke with hyperglycemia, intensive vs standard glucose control did not improve 90-day outcomes
Several factors, including high rates of reperfusion therapy and early hospital discharge, may explain why this trial found no benefit from intensive glucose control after stroke, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/01/10/7.htm
10 Jan 2020
BP-lowering drugs reduced major CV events by similar amounts in patients with and without type 2 diabetes
The results of a large meta-analysis support the conclusion that degree of blood pressure (BP) lowering, rather than the drug used, is the prime driver of cardiovascular (CV) risk reduction from hypertension therapy, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/12/09/9.htm
9 Dec 2022